- Home
- IBRX vs GDV Comparison
IBRX vs GDV Comparison
Compare IBRX & GDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- GDV
- Stock Information
- Founded
- IBRX 2014
- GDV 2003
- Country
- IBRX United States
- GDV United States
- Employees
- IBRX N/A
- GDV N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- GDV Investment Managers
- Sector
- IBRX Health Care
- GDV Finance
- Exchange
- IBRX Nasdaq
- GDV Nasdaq
- Market Cap
- IBRX 2.3B
- GDV 2.2B
- IPO Year
- IBRX N/A
- GDV N/A
- Fundamental
- Price
- IBRX $2.81
- GDV $26.57
- Analyst Decision
- IBRX Strong Buy
- GDV
- Analyst Count
- IBRX 5
- GDV 0
- Target Price
- IBRX $11.40
- GDV N/A
- AVG Volume (30 Days)
- IBRX 7.3M
- GDV 186.0K
- Earning Date
- IBRX 08-11-2025
- GDV 01-01-0001
- Dividend Yield
- IBRX N/A
- GDV 5.81%
- EPS Growth
- IBRX N/A
- GDV N/A
- EPS
- IBRX N/A
- GDV N/A
- Revenue
- IBRX $31,222,000.00
- GDV N/A
- Revenue This Year
- IBRX $567.98
- GDV N/A
- Revenue Next Year
- IBRX $160.56
- GDV N/A
- P/E Ratio
- IBRX N/A
- GDV N/A
- Revenue Growth
- IBRX 10238.41
- GDV N/A
- 52 Week Low
- IBRX $1.83
- GDV $18.04
- 52 Week High
- IBRX $7.48
- GDV $23.00
- Technical
- Relative Strength Index (RSI)
- IBRX 51.33
- GDV 72.05
- Support Level
- IBRX $2.68
- GDV $26.40
- Resistance Level
- IBRX $3.00
- GDV $26.67
- Average True Range (ATR)
- IBRX 0.16
- GDV 0.21
- MACD
- IBRX -0.00
- GDV 0.05
- Stochastic Oscillator
- IBRX 62.00
- GDV 94.85
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About GDV Gabelli Dividend & Income Trust of Beneficial Interest
Gabelli Dividend & Income Trust operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of total return on its assets with an emphasis on dividends and income. To achieve its objective, the fund may invest its assets in dividend-paying securities or other income-producing securities. The fund invests in various sectors, in which Financial Services, Food and Beverage, Health Care, Consumer Products, Electronics, and Computer Software & Services and others.